Evaluating biomarkers in IgA nephropathy patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to investigate the relationship between blood and urine biomarkers, including genetic variants, and the long-term progression of kidney disease in 2000 Chinese patients diagnosed with IgA nephropathy who have relatively normal kidney function. The study focuses on understanding how these biomarkers can predict outcomes in patients with IgA nephropathy, a common cause of end-stage renal disease in China. By integrating data from whole genomic loci and serum and urine biomarkers, the study seeks to provide insights that could lead to better prognostic tools for managing this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female individuals aged 14 years or older
* Patients with biopsy-proven primary IgA nephropathy
* A renal biopsy available for reviewing must include 10 or more glomeruli.
* The first renal biopsy was performed within 3 years.
* eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula);
* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).

Exclusion Criteria:

* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;
* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.

Where it's running

• The First Affiliated Hospital,Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Xue Qing Yu, M.D. & Ph.D. — First Affiliated Hospital, Sun Yat-Sen University
• Study coordinator: Xue Qing Yu, M.D. & Ph.D.
• Email: yuxq@mail.sysu.edu.cn
• Phone: 8620-87766335

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dermal priming to boost flu vaccine response in people on B cell depletion

  This study tests whether applying a topical cream with imiquimod on the skin around vaccination can boost the body’s response to the flu shot in people who are receiving B cell–depleting therapy.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07925996

• JADE101 in IgA Nephropathy: a Phase 2 test in adults

  This Phase 2 open-label study tests JADE101 in adults with IgA nephropathy to see how safe it is and how well it works when added to standard care.

  Recruiting at 22 sites Phase 2 Jade Biosciences, Inc. · Chula Vista, California and 21 other locations · NCT07541287

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

• Anti-CD19/BCMA universal CAR-T (RD06-05) for autoimmune diseases

  This early-phase test gives a universal CAR-T therapy (RD06-05) that targets CD19 and BCMA to adults with autoimmune diseases such as SLE/lupus nephritis, ANCA-associated vasculitis, and anti-GBM disease.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Shanghai, Shanghai Municipality · NCT07203404

• BHV-1400 for IgA nephropathy

  This study will try BHV-1400 in adults with biopsy-confirmed IgA nephropathy to see if the drug is safe and tolerable.

  Recruiting at 15 sites Phase 1 Biohaven Pharmaceuticals, Inc. · Farmington, Connecticut and 14 other locations · NCT07054684

• Nefecon (budesonide) plus ambrisentan for IgA nephropathy with proteinuria

  This test will see if combining Nefecon (a gut‑targeted budesonide) with ambrisentan can reduce urine protein and slow kidney decline in adults with IgA nephropathy who have at least 0.5 g of protein in a 24‑hour urine collection.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07030894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.